Paper Details

  1. Home
  2. Paper Details

A case of refractory intestinal Behçet's disease treated with tocilizumab, a humanised anti-interleukin-6 receptor antibody.

Author: ChenJiali, ChenShi, HeJing

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This case study describes a patient with refractory intestinal Behçet's disease who experienced symptom resolution after receiving tocilizumab, a humanized anti-interleukin-6 receptor antibody. This suggests that tocilizumab may be an effective treatment option for intestinal Behçet's disease that is resistant to conventional therapies.
Paper Details　
Original Abstract of the Article :
We describe a young female patient who had refractory intestinal Behçet's disease that responded to tocilizumab, a humanised anti-interleukin-6 receptor antibody. The patient had suffered from long disease activity courses and was treated with multiple medications, and the disease became refractory ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/28980896

データ提供：米国国立医学図書館（NLM）

Tocilizumab: A New Oasis in the Desert of Refractory Intestinal Behçet's Disease

The desert of [intestinal Behçet's disease] is a challenging one, with many individuals experiencing refractory symptoms despite conventional treatments. This case report explores the use of [tocilizumab], a [humanised anti-interleukin-6 receptor antibody], in a patient with refractory intestinal Behçet's disease. The researchers found that tocilizumab effectively resolved the patient's symptoms, offering a promising new treatment option for individuals with refractory disease.

Tocilizumab: A Potential Treatment for Refractory Intestinal Behçet's Disease

This case report provides a hopeful glimpse into the potential of tocilizumab for treating refractory intestinal Behçet's disease. While further research is needed to establish its efficacy and long-term benefits, this case suggests that tocilizumab may be a valuable option for individuals who haven't responded to conventional treatments.

Behçet's Disease: A Camel's Advice

Behçet's disease is a complex and challenging condition. If you are experiencing symptoms, it’s crucial to seek professional help. A rheumatologist can diagnose and manage Behçet's disease, working with you to develop a personalized treatment plan that addresses your specific needs.

Dr.Camel's Conclusion

This case report highlights the potential of tocilizumab as a promising treatment option for refractory intestinal Behçet's disease. It offers hope for individuals who haven't responded to conventional therapies. However, more research is needed to confirm its efficacy and safety in a larger population.

Date :
  1. Date Completed 2018-02-13
  2. Date Revised 2018-02-13
Further Info :

Pubmed ID

28980896

DOI: Digital Object Identifier

11666

Related Literature

Article Analysis
・Side Effects of sulfasalazine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.